Search

Copyright of Canadian Journal of Agricultural Economics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Industrial biotechnology is an emerging industry in which firms are developing novel alternatives to petroleum-based goods. Canadian-based firms have an opportunity to capitalise on the availability of biomass from Canadian agriculture and Canada's broad resource base. However, complexity of the product development process coupled with immaturity of this industry means little is currently known about these firms, their innovation activities and decision making. This study uses data from the 2003 and 2006 bioproduct development surveys to examine the Canadian bioproducts industry, focusing on factors conducive to innovative activity for bioproduct producing firms. Several factors are important in facilitating innovation, such as intellectual property, collaborations, focus on bioproducts relative to other business activities, the dominant product type and region in which the firm operates. [ABSTRACT FROM AUTHOR]

Factors influencing the development and commercialization of functional food and nutraceutical (FFN) products are explored. Count data models are developed to relate firm, market, and regulatory covariates to the number of FFN product lines firms have under development, on the market, and in total. Canadian firm-level innovation data were taken from Statistics Canada (2003) Functional Food and Nutraceutical Survey. Firms involved in product development/scale-up had more product lines in total and on the market. Firms with a strong and positive perception of the impact of regulatory reform related to generic health claims and harmonization of Canadian regulations with U.S. regulations had fewer product lines in total and on the market. Firms with more positive perceptions of the business impact of structure and function health claims had more product lines on the market. One implication of the study is the importance of developing policies and reforming regulations which better enable use of generic health claims on FFN products. Further, policies which better enable or foster development/scale-up of product lines would increase the Canadian FFN sector's ability to develop new products. [EconLit: O130, L500, Q180]. © 2008 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]

Under the North American Free Trade Agreement (NAFTA), there has been a dramatic increase in the integration of markets for live cattle and beef products in Canada, Mexico, and the United States. These markets were severely disrupted in 2003 by the confirmation of single cases of bovine spongiform encephalopathy (BSE) in Canada and the United States. The bulk of this disruption could have been avoided if the countries had developed more closely coordinated risk management programs based on the guidance of international standards. The BSE events illustrate that failure to address regulatory integration leaves integrated markets vulnerable to recurring disruptions. [ABSTRACT FROM AUTHOR]

Analyzes the strategies of independent, domestically owned medium-sized processing companies in Canada. Details on the theoretical concept of a core competence; Competition for agricultural food firms; Role of internal factors in the strategies of meduimd-size food processors.

Focuses on the history of the development of Rol-Land Farms Ltd., a dairy farm in Ontario. Details on the incorporation of the family farm lands in 1971; Investment in a mushroom production facility for the existing land base; Achievements of the owners of the dairy farm; Product lines of the dairy farm.

Advancement in biotechnology requires continued innovative activity by firms. To grow, biotechnology firms must understand the factors affecting their innovative activity. Such understanding also informs policy makers, and supports the development of policies promoting one's biotechnology sector. This study explores factors, which determine innovative activity within the Canadian biotechnology industry. Innovative activity is measured as the natural log of the number of products/processes a firm has at different stages of the innovation spectrum. A model is developed to regress this measure on several determinants of innovation. Significant drivers of innovation include: collaborative arrangements, transfer of intellectual property, firm size and age, whether the firm was in the agricultural or human health biotechnology sectors and whether the firm focused on development or commercialisation. Generally speaking, these factors all contributed to firms having more products/processes either under development, undergoing clinical trials or regulatory approval, or on the market. [ABSTRACT FROM AUTHOR]